EP Patent

EP0603312A4 — Novel gaba a? receptor with steroid binding sites.

Assigned to Cocensys Inc · Expires 1995-06-07 · 31y expired

What this patent protects

There is disclosed a GABAA receptor-chloride ionophore complex (GRC), where GABA represents gamma-aminobutyric acid, having a novel binding site, the GNR, independent of other known sites on the GRC. There is also disclosed a method for screening for agonists of the GNR by formin…

USPTO Abstract

There is disclosed a GABAA receptor-chloride ionophore complex (GRC), where GABA represents gamma-aminobutyric acid, having a novel binding site, the GNR, independent of other known sites on the GRC. There is also disclosed a method for screening for agonists of the GNR by forming an expressed GRC by co-expression cDNA encoding the GRC subunits in cells and determining the ability of a steroid to modulate allosterically benzodiazepine binding to the expressed receptor complex. The figure shows the enhancement of the binding of a benzodiazepine analog to the GRC as a function of the concentration of a steroid modulator which binds to the GNR.

Drugs covered by this patent

Patent Metadata

Patent number
EP0603312A4
Jurisdiction
EP
Classification
—
Expires
1995-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Cocensys Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.